Whenever a company enters a particularly valuable industry, there is bound to be a degree of excitement among market participants, and on Monday, Adia Nutrition Inc. (OTC: ADIA) made such an announcement. The company announced yesterday that it had made a move to enter the highly lucrative worldwide stem cell market.
New Horizons
Yesterday, Adia Nutrition announced that it had made strategic moves through its medical division, Adia Med, to capture a major share of the worldwide stem cell market worth as much as $15.1 billion. In the news release, the company announced that its business unit’s clinic located in Winter Park in Florida offered a range of stem cell treatments that utilized as many as 361 human cells, tissue, and tissue-based products. The aim had been to provide a service that could match the services provided by the very best in the world.
Further Information
The company further observed in the news release that with the expansion of the worldwide stem cell market, Adia Nutrition found an opportunity to make these treatments considerably more accessible to those in the United States. It may be a good idea to add the Adia Nutrition stock to your watch lists at this point.
Key Quote
“With the global stem cell market expanding, we see an opportunity to make these treatments more accessible in the U.S.,” said Larry Powalisz, CEO of Adia Nutrition. “Adia Med focuses on delivering care with advanced, ethically sourced umbilical cord stem cells.”
Technicals
| +/- EMA(20) | 0.015 (+113.33%) |
| +/- SMA(50) | 0.0097 (+229.90%) |
| +/- SMA(200) | 0.0095 (+236.84%) |
| 5-Day Perf. | +146.15% |
| 1-Month Perf. | +229.9% |
| 3-Month Perf. | +540% |
| 6-Month Perf. | +220% |
| YTD Perf. | +392.31% |
| 1-Year Perf. | +210.68% |
| RSI(14) | 89.75 |
| ATR(14) | – |
| ADX(14) | 27.57 |
